PharmaEssentia Corp (藥華醫藥) yesterday said that phase-three European clinical trials for its bone marrow disease treatment may be completed three months earlier than expected, as its European partner is likely to register a sufficient number of subjects soon.
PharmaEssentia chairman Jan Ching-leou (詹青柳) said AOP Orphan Pharmaceuticals AG may be able to recruit 256 people with polycythemia vera in Europe by the end of next quarter, rather than by the end of this year as it projected earlier.
As a result, the two companies are expected to launch its P1101 (AOP2014) protein drug in Europe by the end of 2016, instead of 2017, Jan said.
Last month, the Taiwanese firm filed an investigational new drug (IND) application with US authorities, said Ellen Chang (張慧敏), a financial department director at PharmaEssentia.
It might take about a month for the US Food and Drug Administration (FDA) to decide whether the company can use the European clinical trial data for its permit application in the US, she added.
If the US FDA approves PharmaEssentia’s proposal, the company expects to launch the drug in the US at the same time as in Europe, Chang said.
Based on the company’s estimates, it will take three to five years for sales of the drug to reach peak sales, which are expected to be about US$1 billion a year in the US, and the same in Europe.
There are about 149,000 people in the US with polycythemia vera, a blood disorder in which the bone marrow makes too many red blood cells. In Europe, about 100,000 people have the disease.
The company said P1101 is more potent and has fewer side effects than the existing Jakafi treatment, launched by US-based Incyte Corp last year.
PharmaEssentia said it plans to price P1101 lower than Jakafi, which costs patients US$120,240 a year, to gain market share.
Meanwhile, PharmaEssentia on Monday applied to the Ministry of Economic Affairs to be recognized as a technology enterprise, so it can shift its stock listing to the GRETAI Securities Market next year.
In related news, drugmaker Medigen Biotechnology Corp (基亞生技) yesterday said that it is able to start the interim analysis of its data for phase three clinical trials of PI-88 treatment for liver cancer in Taiwan, China, Hong Kong and South Korea.
The company is to review the data on July 27 and disclose the results immediately after the reviewing meeting.
If the analysis yields positive results, Medigen expects to acquire a drug permit in Taiwan by the end of this year.
WASHINGTON’S INCENTIVES: The CHIPS Act set aside US$39 billion in direct grants to persuade the world’s top semiconductor companies to make chips on US soil The US plans to award more than US$6 billion to Samsung Electronics Co, helping the chipmaker expand beyond a project in Texas it has already announced, people familiar with the matter said. The money from the 2022 CHIPS and Science Act would be one of several major awards that the US Department of Commerce is expected to announce in the coming weeks, including a grant of more than US$5 billion to Samsung’s rival, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), people familiar with the plans said. The people spoke on condition of anonymity in advance of the official announcements. The federal funding for
HIGH DEMAND: The firm has strong capabilities of providing key components including liquid cooling technology needed for AI servers, chairman Young Liu said Hon Hai Precision Industry Co (鴻海精密) yesterday revised its revenue outlook for this year to “significant” growth from a “neutral” view forecast five months ago, due to strong demand for artificial intelligence (AI) servers from cloud service providers. Hon Hai, a major assembler of iPhones that is also known as Foxconn, expects AI server revenues to soar more than 40 percent annually this year, chairman Young Liu (劉揚偉) told investors. The robust growth would uplift revenue contribution from AI servers to 40 percent of the company’s overall server revenue this year, from 30 percent last year, Liu said. In the three-year period
LONG HAUL: Largan Energy Materials’ TNO-based lithium-ion batteries are expected to charge in five minutes and last about 20 years, far surpassing conventional technology Largan Precision Co (大立光) has formed a joint venture with the Industrial Technology Research Institute (ITRI, 工研院) to produce fast-charging, long-life lithium-ion batteries for electric vehicles, mobile electronics and electric storage units, the camera lens supplier for Apple Inc’s iPhones said yesterday. Largan Energy Materials Co (萬溢能源材料), established in January, is developing high-energy, fast-charging, long-life lithium-ion batteries using titanium niobium oxide (TNO) anodes, it said. TNO-based batteries can be fully charged in five minutes and have a lifespan of 20 years, a major advantage over the two to four hours of charging time needed for conventional graphite-anode-based batteries, Largan said in a
Taiwan is one of the first countries to benefit from the artificial intelligence (AI) boom, but because that is largely down to a single company it also represents a risk, former Google Taiwan managing director Chien Lee-feng (簡立峰) said at an AI forum in Taipei yesterday. Speaking at the forum on how generative AI can generate possibilities for all walks of life, Chien said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) — currently among the world’s 10 most-valuable companies due to continued optimism about AI — ensures Taiwan is one of the economies to benefit most from AI. “This is because AI is